| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 7 | | | |
| | | | 13 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 18 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 20 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | 22 | | | |
| | | | 23 | | | |
| | | | 23 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 28 | | | |
| | | | 33 | | | |
| | | | 40 | | | |
| | | | 41 | | | |
| | | | 43 | | | |
| | | | 45 | | | |
| | | | 49 | | | |
| | | | 51 | | | |
| | | | 57 | | | |
| | | | 58 | | | |
| | | | 59 | | | |
| | | | 68 | | | |
| | | | 68 | | | |
| | | | 68 | | | |
| | | | 68 | | | |
| | | | 69 | | | |
| | | | 70 | | | |
| | | | 71 | | | |
| | | | 72 | | | |
| | | | 73 | | | |
| | | | 82 | | |
| | |
Page
|
| |||
| | | | 83 | | | |
| | | | 85 | | | |
| | | | 87 | | | |
| | | | 90 | | | |
| | | | 90 | | | |
| | | | 90 | | | |
| | | | A-1 | | | |
| | | | B-1 | | | |
| | | | C-1 | | |
Proposal
|
| |
Vote
Required |
| |
Broker
Discretionary Voting Allowed |
| |||
Election of Directors
|
| |
Majority of
Votes Cast |
| | | | No | | |
Ratification of KPMG
|
| |
Majority of
Votes Cast |
| | | | Yes | | |
Amendment to our 2008 Stock Incentive Plan (Amended and Restated as of
April 15, 2015) |
| |
Majority of
Votes Cast |
| | | | No | | |
Advisory Approval of our 2015 Named Executive Officer Compensation
(non-binding) |
| |
Majority of
Votes Cast |
| | | | No | | |
Ratification of By-law Amendment
|
| |
Majority of
Votes Cast |
| | | | No | | |
Stockholder Proposals (non-binding)
|
| |
Majority of
Votes Cast |
| | | | No | | |
Name
|
| |
Age(1)
|
| |
Position
|
| |||
Robert J. Hugin
|
| | | | 61 | | | |
Executive Chairman of the Board
|
|
Mark J. Alles
|
| | | | 57 | | | |
Director and Chief Executive Officer
|
|
Richard W. Barker, D.Phil.
|
| | | | 67 | | | |
Director
|
|
Michael W. Bonney
|
| | | | 57 | | | |
Director
|
|
Michael D. Casey
|
| | | | 70 | | | |
Director
|
|
Carrie S. Cox
|
| | | | 58 | | | |
Director
|
|
Jacqualyn A. Fouse, Ph.D.
|
| | | | 55 | | | |
Director and President and Chief Operating Officer
|
|
Michael A. Friedman, M.D.
|
| | | | 72 | | | |
Director
|
|
Julia A. Haller, M.D.
|
| | | | 61 | | | |
Director
|
|
Gilla Kaplan, Ph.D.
|
| | | | 69 | | | |
Director
|
|
James J. Loughlin
|
| | | | 73 | | | |
Director
|
|
Ernest Mario, Ph.D.
|
| | | | 78 | | | |
Director
|
|
Name and Address of Beneficial Ownership
|
| |
Amount and Nature of
Beneficial Ownership |
| |
Percent
of Class |
| ||||||
Robert J. Hugin
|
| | | | 4,021,515(1) | | | | | | * | | |
Mark J. Alles
|
| | | | 412,818(2) | | | | | | * | | |
Thomas O. Daniel, M.D.
|
| | | | 369,445(3) | | | | | | * | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 785,412(4) | | | | | | * | | |
Peter N. Kellogg
|
| | | | 170,574(5) | | | | | | * | | |
Scott A. Smith
|
| | | | 286,165(6) | | | | | | * | | |
Richard W. Barker, D.Phil.
|
| | | | 100,118(7) | | | | | | * | | |
Michael W. Bonney
|
| | | | 22,000(8) | | | | | | * | | |
Michael D. Casey
|
| | | | 343,468(9) | | | | | | * | | |
Carrie S. Cox
|
| | | | 121,413(10) | | | | | | * | | |
Michael A. Friedman, M.D.
|
| | | | 137,482(11) | | | | | | * | | |
Julia A. Haller, M.D.
|
| | | | 10,200(12) | | | | | | * | | |
Gilla Kaplan, Ph.D.
|
| | | | 296,701(13) | | | | | | * | | |
James J. Loughlin
|
| | | | 252,068(14) | | | | | | * | | |
Ernest Mario, Ph.D.
|
| | | | 169,799(15) | | | | | | * | | |
All directors and executive officers as a group (16 persons)
|
| | | | 7,546,563(1)–(15) | | | | | | * | | |
BlackRock, Inc.
|
| | | | 53,056,161(16) | | | | | | 6.8% | | |
55 East 52nd Street
|
| | | | | | | | |||||
New York, New York 10055
|
| | | | | | | | |||||
Vanguard Group, Inc.
|
| | | | 46,398,324(17) | | | | | | 6.0% | | |
100 Vanguard Blvd.
|
| | | | | | | | |||||
Malvern, PA 19355
|
| | | | | | | |
|
Name
|
| |
Title (as of December 31, 2015)
|
|
|
Robert J. Hugin*
|
| | Chief Executive Officer and Chairman of the Board | |
|
Peter N. Kellogg
|
| | Executive Vice President, Chief Financial Officer | |
|
Mark J. Alles*
|
| | President and Chief Operating Officer | |
|
Thomas O. Daniel, M.D.
|
| | President, Research and Early Development | |
|
Jacqualyn A. Fouse, Ph.D.*
|
| | President Hematology and Oncology | |
|
Scott A. Smith
|
| | President, Inflammation & Immunology | |
| |
Financial Performance
Revenue (28% of MIP target): Adjusted (non-GAAP (generally accepted accounting principles) total revenue of $9.256 billion, a 21% increase year over year. Contributing to this was:
◦
REVLIMID® sales of $5.801 billion, an increase of 16%
◦
POMALYST®/IMNOVID® sales of $983 million, an increase of 45%
◦
ABRAXANE® sales of $967 million, an increase of 14%
◦
OTEZLA® sales of $472 million
Earnings Per Share (EPS) (28% of MIP target): Adjusted (non-GAAP) diluted EPS of $4.71, a 27% increase year over year.
These and other 2015 accomplishments, which represent 44% of the overall MIP target, are reflected in our above-target score of 101.375% under our annual cash bonus program, or Management Incentive Plan (MIP).
For more information, please see the description of non-GAAP financial achievements in “Key 2015 Compensation Actions and Program Highlights — Annual Bonus (MIP) Payout for Fiscal 2015” and Appendix A — Reconciliation of GAAP to Adjusted (Non-GAAP) Net Income.
|
| |
| |
Delivering Value to Our Stockholders
Our stock price increased over 7% in fiscal 2015 from the prior fiscal year-end. Our three-year Total Shareholder Return (TSR)* through December 31, 2015 was 187.57%, which approximates the 79th percentile of the relative comparator group for TSR as selected by our Compensation Committee at the commencement of the 2013-2015 plan cycle. Relative Total Shareholder Return and its role in our pay-for-performance philosophy under our Long-Term Incentive Plan (“LTIP”) are further described in “Highlights of Best Practices of Our Compensation Programs” and “Long-Term Incentives.”
*
Under our Long-Term Incentive Plan (LTIP) and Performance Stock Units (PSUs), TSR is calculated as the percent change in our common stock price at the beginning and the end of each performance cycle, calculated as the difference between the average closing price of our common stock in the 30 trading days preceding the commencement of each performance cycle and the average closing price of our common stock in the final 30 trading days of each performance cycle.
|
| |
| AbbVie Inc. | | | Bristol-Myers Squibb Company | |
| Allergan, plc* | | | Eli Lilly and Company | |
| Amgen Inc. | | | Forest Laboratories, Inc.* | |
| Baxter International Inc. | | | Gilead Sciences Inc. | |
| Biogen Idec Inc. | | | Valeant Pharmaceuticals International, Inc.** | |
|
Compensation Recovery
|
| | |
In the event of an executive’s fraud or misconduct that results in a material negative restatement of our financial statements, with respect to the year to which the restatement applies (excluding any year before January 1, 2013 for our CEO and before January 1, 2014 for our other NEOs) and for any single year prior to the year in which the Company is required to prepare the restatement, we may recoup any or all of the incentive compensation paid to that executive in excess of the amounts that would have been paid to that executive based on the restated results. We may also cancel unvested incentive compensation or require the executive to repay any gains realized by the executive in excess of the amount that would have been paid to that executive based on the restated results.
|
|
|
Risk Mitigation
|
| | |
We proactively review our compensation programs and policies to ensure they are reflective of our philosophy with regard to risk. The plan features below are designed to promote each NEO’s focus on making decisions that promote a responsible and balanced risk profile:
◦
Diversification and balance of short- and long-term rewards
◦
Multiple metrics within each variable pay program that are balanced and weighted so as not to encourage focus on a single metric to the exclusion of others
◦
Maximum payout caps for all variable and performance-based plans
◦
Share ownership requirements for our NEOs
◦
Holding requirements on shares earned under our Long-Term Incentive Plan (LTIP) and on vested, earned Performance Stock Units (PSUs) of at least one year and one day
◦
Pre-established grant dates for NEOs’ equity awards as set by our Compensation Committee
|
|
|
Share Ownership Requirements
|
| | |
In order to ensure that our NEOs continue to have a significant stake in our long-term performance and to align executives’ compensation to the interests of stockholders, we have robust share ownership guidelines for our NEOs. Each of our Executive Chairman and CEO has a share ownership requirement equal to a value of six times his respective annual base salary. Each of our other NEOs’ share ownership requirement is equal to a value of three times annual base salary. These guidelines will be satisfied if the NEO holds, by the end of the applicable five-year period, at least the number of shares of our Common Stock equal to the value of the target amount divided by our stock price on the date the NEO becomes subject to the guidelines. Owned shares, vested restricted or deferred stock units, and vested shares held in the NEO’s 401(k) plan account are included in ownership calculations, but stock options, unvested RSUs and unvested PSUs are not. With the exception of Mr. Kellogg, who was hired in fiscal 2014, all of our NEOs meet or exceed their stock ownership requirements.
|
|
|
Holding Periods
|
| | |
In addition to share ownership requirements, there is a holding period on all shares granted to NEOs under the LTIP and on all vested, earned PSUs of at least one year and one day. These holding periods further align compensation and value delivered to stock performance and long-term value to our stockholders.
|
|
|
No Repricing
|
| | |
Our 2008 Stock Incentive Plan (amended and restated as of April 15, 2015), or the 2008 Stock Incentive Plan, prohibits us from modifying stock options to reduce the exercise price, substituting a new stock option at a lower price for a surrendered stock option or repurchasing stock options if the per share exercise price is less than the fair market value of a share of Common Stock, in each case, unless such action is approved by our stockholders.
|
|
|
Securities Trading Policy
|
| | |
We maintain a comprehensive securities trading policy which provides, among other things, that our employees who possess material non-public information regarding us may not disclose, or trade while in possession of such information or buy or sell our securities during any designated blackout period. Further, the policy prohibits all employees from short-selling our securities, transacting in derivative securities relating to Celgene without prior written consent of our Chief Executive Officer or holding our stock in a margin account or pledging our stock as collateral for a loan without prior approval of an appropriate officer of the Company. Individuals classified as “insiders” (which includes our NEOs) and related persons (as defined in the policy) generally may not buy or sell our securities at any time without prior approval, except under approved Rule 10b5-1 trading plans.
|
|
|
No Golden Parachute Gross-Up Payments
|
| | |
None of our NEOs currently have an agreement with the Company whereby we would be obligated to pay a gross-up for excise taxes in excess of parachute payments as defined in Internal Revenue Code (IRC) Section 280G.
|
|
|
Change in Control Double-Trigger
|
| | |
In 2011, we amended our 2008 Stock Incentive Plan to eliminate the “single-trigger” change in control vesting provision for equity awards granted on or after July 1, 2011 and to provide that, unless otherwise determined at grant, such equity awards vest only upon an involuntary termination of employment without cause that occurs within two years following a change in control (i.e., a “double trigger”).
|
|
|
Relative Total Stockholder Return (R-TSR)
|
| | |
A portion of each NEOs’ long-term compensation is based on R-TSR, either through our active LTIP performance cycles or, beginning in fiscal 2015, through PSUs. R-TSR is calculated as the percent change in our stock price from the beginning to the end of a measurement period compared to an identified comparator group of companies for the same period, which is then expressed as a percentile. This measure ensures that executive pay realized through long-term compensation is aligned to our stock performance and value delivered to our stockholders as compared to our identified comparator group.
|
|
|
NEO Compensation Cost Analysis
|
| | |
To ensure that our compensation programs remain aligned with the interests of our stockholders and to further reinforce a team-based approach to management, we measure our NEOs’ collective compensation in relation to the collective compensation paid to named executive officers of companies within our peer group as an additional data point when making compensation decisions for our NEOs.
|
|
|
|
| |
|
|
|
Approximately 77% of our CEO’s overall pay is long-term equity-based and 90% (which includes short-term bonus and equity compensation) is performance-based. Other compensation is approximately 1% of overall pay.
|
| |
Approximately 70% of our Other NEOs’ overall pay is long-term equity-based and 83% (which includes short-term bonus and equity compensation) is performance-based. Other compensation is approximately 1% of overall pay.
|
|
Type
|
| | |
General Terms
|
|
Stock Options
|
| | |
•
Granted upon hire, then annually (issued on a quarterly basis)
•
Service-based vesting over four years (25% per year)
•
Ten-year term
•
Subject to recovery
|
|
Restricted Stock Units (RSUs)
|
| | |
•
Granted upon hire, then annually
•
Opportunity for additional annual grant based on achievement of performance objectives and value creation
•
Service-based cliff vesting (generally, 100% vested on third anniversary of grant date)
•
Subject to recovery
|
|
LTIP
|
| | |
•
LTIP awards can be paid in cash, restricted shares of our Common Stock or a combination thereof, as determined by the Compensation Committee
•
Awards are based on attainment of performance metrics, weighted as follows:
◦
Adjusted Revenue (37.5% weighting)
◦
Adjusted Earnings Per Share (37.5% weighting)
◦
R-TSR (Relative- Total Shareholder Return) (25% weighting)
•
All earned shares are subject to holding periods of at least one year and one day
•
Subject to recovery
•
NEOs no longer participate in new LTIP performance cycles
|
|
Performance Stock Units (PSUs)
|
| | |
•
Granted annually, commencing in fiscal 2015
•
Three-year vesting and measurement period, subject to attainment of defined, weighted metrics established by the Compensation Committee prior to the grant (see “Mix of Equity Awards” below for more information)
•
Maximum award is 200% of target units
•
All earned PSUs must be held for one year and one day from the vesting date
•
Subject to recovery
|
|
Type
|
| | |
General Terms
|
|
General Provisions for Death, Disability, Termination as a result of Change in Control and Retirement for Stock Options, RSUs and PSUs
|
| | |
•
In the event of death, permanent disability or termination without cause within two years as a result of a change in control (double-trigger), the vesting of stock options and RSUs will accelerate, and the vesting of the PSUs will accelerate and shares will be payable based on actual plan performance as of the last day of the calendar quarter preceding the date of death, disability or termination without cause during the two year period commencing on a change in control.
•
If the NEO (other than our Executive Chairman) attains retirement as defined in the 2008 Stock Incentive Plan and has given at least six months’ notice of the intent to retire, as of the date of retirement:
◦
RSUs granted on or after April 29, 2013 will vest on retirement, but will be payable on the earliest of death, disability or the originally scheduled vesting date
◦
PSUs will continue to vest and a pro rata portion (based on number of completed months of employment during the performance period) will be payable at the end of the performance period based on actual results
◦
Stock options will continue to vest and will remain exercisable until the earlier of three years after retirement or the original option expiration date
•
If our Executive Chairman attains retirement as defined in the 2008 Stock Incentive Plan, any vesting and payment of his stock options, RSUs and PSUs will occur in accordance with the terms of his employment agreement and the applicable award agreement
|
|
Measurements & Weights
|
| |
Threshold, Target & Maximum
of Financial Measures |
| |||
Adjusted Revenue | | |
37.5%
|
| |
90% – 100% – 110%
|
|
Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 110%
|
|
R-TSR(1) | | |
25%
|
| |
35th – 50th – 80th
(percentiles) |
|
Performance Cycle
|
| |
Measurements & Weights
|
| |
Threshold, Target & Maximum
of Financial Measures |
| |||
2013–2015(1) | | | Adjusted Revenue | | |
37.5%
|
| |
90% – 100% – 125%
|
|
| | | Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 125%
|
|
| | | R-TSR | | |
25%
|
| |
50th – 70th – 90th
(percentiles) |
|
2014–2016(2) | | | Adjusted Revenue | | |
37.5%
|
| |
90% – 100% – 110%
|
|
| | | Adjusted EPS | | |
37.5%
|
| |
90% – 100% – 110%
|
|
| | | R-TSR | | |
25%
|
| |
35th – 50th – 80th
(percentiles) |
|
NEO
|
| |
2014 Salary
|
| |
2015 Salary
|
| |
Effective Date
of Salary Adjustment |
| |
2016 Salary
|
| |
Effective Date
of Salary Adjustment |
| |||||||||||||||
Robert J. Hugin
|
| | | $ | 1,400,000 | | | | | $ | 1,500,000 | | | | | | 3/1/2015 | | | | | $ | 1,500,000 | | | | | | — | | |
Peter Kellogg
|
| | | $ | 800,000 | | | | | $ | 824,000 | | | | | | 3/1/2015 | | | | | $ | 850,000 | | | | | | 3/1/2016 | | |
Mark J. Alles*
|
| | | $ | 850,000 | | | | | $ | 875,500 | | | | | | 3/1/2015 | | | | | $ | 1,100,000 | | | | | | 3/1/2016 | | |
Thomas O. Daniel, M.D.
|
| | | $ | 700,000 | | | | | $ | 721,000 | | | | | | 3/1/2015 | | | | | $ | 721,000 | | | | | | — | | |
Jacqualyn A. Fouse, Ph.D.*
|
| | | $ | 825,000 | | | | | $ | 849,800 | | | | | | 3/1/2015 | | | | | $ | 960,000 | | | | | | 3/1/2016 | | |
Scott A. Smith
|
| | | $ | 600,000 | | | | | $ | 650,000 | | | | | | 3/1/2015 | | | | | $ | 700,000 | | | | | | 3/1/2016 | | |
NEO
|
| |
Bonus
Target for Fiscal 2015 |
| |
Corporate
Weighting X Corporate Score |
| |
Bonus Paid
2/29/2016 |
| |
2016
Target |
| |||||||||
Robert J. Hugin
|
| | | | 150% | | | |
100% x 101.375%
|
| | | $ | 2,255,594 | | | | | | 125% | | |
Peter Kellogg
|
| | | | 70% | | | |
100% x 101.375%
|
| | | $ | 581,893 | | | | | | 75% | | |
Mark J. Alles
|
| | | | 90% | | | |
100% x 101.375%
|
| | | $ | 794,907 | | | | | | 125% | | |
Thomas O. Daniel, M.D.
|
| | | | 70% | | | |
100% x 101.375%
|
| | | $ | 509,156 | | | | | | 70% | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 80% | | | |
100% x 101.375%
|
| | | $ | 685,836 | | | | | | 90% | | |
Scott A. Smith
|
| | | | 75% | | | |
100% x 101.375%
|
| | | $ | 487,867 | | | | | | 80% | | |
| | | | | | | | | | | | | | |
PSUs(3)
|
| |||||||||||||||
Name
|
| |
Stock Options(1)
|
| |
RSUs(2)
|
| |
Threshold
|
| |
Target
|
| |
Max
|
| |||||||||||||||
Robert J. Hugin
|
| | | | 201,600(4) | | | | | | 16,300(5) | | | | | | 14,700 | | | | | | 29,400 | | | | | | 58,800(5) | | |
Peter Kellogg
|
| | | | 36,050(6) | | | | | | 11,536(8)(9) | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400(8) | | |
Mark J. Alles
|
| | | | 36,050(6) | | | | | | 12,429(8)(9) | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400(8) | | |
Thomas O. Daniel, M.D.
|
| | | | 36,050(6) | | | | | | 10,643(8)(9) | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400(8) | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 36,050(6) | | | | | | 11,982(8)(9) | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400(8) | | |
Scott A. Smith
|
| | | | 30,875(7) | | | | | | 11,536(8)(9) | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400(8) | | |
Name
|
| |
2013−2015 Payout(1)(2)
|
| |||
Robert J. Hugin
|
| | | | 49,922 shares | | |
Peter N. Kellogg
|
| | | | 7,822 shares | | |
Mark J. Alles
|
| | | | 25,840 shares | | |
Thomas O. Daniel, M.D.
|
| | | | 25,045 shares | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 29,219 shares | | |
Scott A. Smith
|
| | | $ | 372,566 | | |
Name
|
| |
Threshold(1)(4)
|
| |
Target(2)(4)
|
| |
Maximum(3)(4)
|
| |||||||||
Robert J. Hugin
|
| | | $ | 640,000 | | | | | $ | 1,600,000 | | | | | $ | 2,560,000 | | |
| | | 7,810 shares | | | | | | 19,526 shares | | | | | | 31,240 shares | | | ||
Peter N. Kellogg
|
| | | $ | 333,333 | | | | | $ | 666,667 | | | | | $ | 1,333,333 | | |
| | | 4,155 shares | | | | | | 8,310 shares | | | | | | 16,621 shares | | | ||
Mark J. Alles
|
| | | $ | 335,000 | | | | | $ | 670,000 | | | | | $ | 1,340,000 | | |
| | | 4,088 shares | | | | | | 8,176 shares | | | | | | 16,352 shares | | | ||
Thomas O. Daniel, M.D.
|
| | | $ | 324,500 | | | | | $ | 649,000 | | | | | $ | 1,298,000 | | |
| | | 3,960 shares | | | | | | 7,920 shares | | | | | | 15,840 shares | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| | | $ | 378,500 | | | | | $ | 757,000 | | | | | $ | 1,514,000 | | |
| | | 4,618 shares | | | | | | 9,238 shares | | | | | | 18,476 shares | | | ||
Scott A. Smith
|
| | | $ | 122,500 | | | | | $ | 245,000 | | | | | $ | 490,000 | | |
Name
|
| |
Matching Contributions under the 401(k) Plan(1)
|
|
Robert J. Hugin
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Peter Kellogg
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Mark J. Alles
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Thomas O. Daniel, M.D
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Jacqualyn A. Fouse, Ph.D.
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Scott A. Smith
|
| |
135.15572 shares of Common Stock (fair value of $16,186)
|
|
Name
|
| |
Age(1)
|
| |
Position
|
| |||
Robert J. Hugin
|
| | | | 61 | | | |
Executive Chairman (formerly Chairman and Chief Executive Officer)(2)
|
|
Mark J. Alles
|
| | | | 57 | | | |
Chief Executive Officer (formerly President and Chief Operating Officer)(2)
|
|
Peter N. Kellogg
|
| | | | 60 | | | | Executive Vice President and Chief Financial Officer | |
Thomas O. Daniel, M.D.
|
| | | | 62 | | | | Chairman, Celgene Research | |
Jacqualyn A. Fouse, Ph.D.
|
| | | | 55 | | | |
President and Chief Operating Officer (formerly President Hematology and Oncology)(2)
|
|
Scott A. Smith
|
| | | | 54 | | | | President, Inflammation & Immunology | |
Gerald F. Masoudi
|
| | | | 48 | | | |
Executive Vice President, General Counsel and Corporate Secretary
|
|
Name and Principal Position (as of 12/31/15)
|
| |
Year
|
| |
Salary
|
| |
Bonus(1)
|
| |
Stock
Awards(2) |
| |
Option
Awards(2) |
| |
Non-Equity
Incentive Plan Compensation(3) |
| |
Change in
Pension Value and Nonqualified Deferred Compensation Earnings(4) |
| |
All Other
Compensation(5) |
| |
Total
|
| ||||||||||||||||||||||||
(a)
|
| |
(b)
|
| |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(f)
|
| |
(g)
|
| |
(h)
|
| |
(i)
|
| |
(j)
|
| ||||||||||||||||||||||||
Robert J. Hugin
CEO and Chairman(6) |
| |
2015
|
| | | $ | 1,483,333 | | | | | | — | | | | | $ | 5,431,237 | | | | | $ | 7,944,888 | | | | | $ | 7,370,103 | | | | | | — | | | | | $ | 243,351 | | | | | $ | 22,472,912 | | |
|
2014
|
| | | $ | 1,380,000 | | | | | | — | | | | | $ | 3,899,980 | | | | | $ | 9,614,448 | | | | | $ | 9,110,269 | | | | | | — | | | | | $ | 231,416 | | | | | $ | 24,236,113 | | | ||
|
2013
|
| | | $ | 1,262,500 | | | | | | — | | | | | $ | 3,554,100 | | | | | $ | 8,729,638 | | | | | $ | 7,236,693 | | | | | | — | | | | | $ | 212,854 | | | | | $ | 20,995,785 | | | ||
Peter N. Kellogg
Executive Vice President and Chief Financial Officer |
| |
2015
|
| | | $ | 820,000 | | | | | | — | | | | | $ | 2,072,789 | | | | | $ | 1,405,470 | | | | | $ | 1,383,257 | | | | | | — | | | | | $ | 24,120 | | | | | $ | 5,705,636 | | |
|
2014
|
| | | $ | 400,000 | | | | | | — | | | | | $ | 5,815,094 | | | | | $ | 3,313,252 | | | | | $ | 560,000 | | | | | | — | | | | | $ | 9,098 | | | | | $ | 10,097,444 | | | ||
Mark J. Alles
President and Chief Operating Officer |
| |
2015
|
| | | $ | 871,250 | | | | | | — | | | | | $ | 2,176,127 | | | | | $ | 1,405,470 | | | | | $ | 3,442,215 | | | | | | — | | | | | $ | 17,109 | | | | | $ | 7,912,171 | | |
|
2014
|
| | | $ | 767,917 | | | | | | — | | | | | $ | 901,257 | | | | | $ | 2,077,620 | | | | | $ | 4,278,167 | | | | | | — | | | | | $ | 21,272 | | | | | $ | 8,046,233 | | | ||
|
2013
|
| | | $ | 666,667 | | | | | | — | | | | | $ | 1,186,586 | | | | | $ | 2,440,484 | | | | | $ | 3,188,449 | | | | | | — | | | | | $ | 20,511 | | | | | $ | 7,502,697 | | | ||
Thomas O. Daniel, M.D.
Chairman, Celgene Research |
| |
2015
|
| | | $ | 717,500 | | | | | | — | | | | | $ | 1,969,451 | | | | | $ | 1,405,470 | | | | | $ | 3,075,016 | | | | | | — | | | | | $ | 174,541 | | | | | $ | 7,341,978 | | |
|
2014
|
| | | $ | 691,500 | | | | | | — | | | | | $ | 767,672 | | | | | $ | 1,921,324 | | | | | $ | 4,141,720 | | | | | | — | | | | | $ | 148,364 | | | | | $ | 7,670,580 | | | ||
|
2013
|
| | | $ | 645,833 | | | | | | — | | | | | $ | 1,059,360 | | | | | $ | 2,269,123 | | | | | $ | 3,165,006 | | | | | | — | | | | | $ | 100,434 | | | | | $ | 7,239,756 | | | ||
Jacqualyn A. Fouse, Ph.D.
President Hematology and Oncology |
| |
2015
|
| | | $ | 845,667 | | | | | | — | | | | | $ | 2,124,401 | | | | | $ | 1,405,470 | | | | | $ | 3,679,323 | | | | | | — | | | | | $ | 18,641 | | | | | $ | 8,073,502 | | |
|
2014
|
| | | $ | 803,250 | | | | | | — | | | | | $ | 901,257 | | | | | $ | 2,077,620 | | | | | $ | 4,867,123 | | | | | | — | | | | | $ | 22,238 | | | | | $ | 8,671,488 | | | ||
|
2013
|
| | | $ | 753,333 | | | | | | — | | | | | $ | 1,059,360 | | | | | $ | 2,269,123 | | | | | $ | 3,692,296 | | | | | | — | | | | | $ | 21,829 | | | | | $ | 7,795,941 | | | ||
Scott A. Smith
President, Immunology & Inflammation |
| |
2015
|
| | | $ | 641,667 | | | | | | — | | | | | $ | 2,072,789 | | | | | $ | 1,189,715 | | | | | $ | 860,433 | | | | | | — | | | | | $ | 18,641 | | | | | $ | 4,783,245 | | |
|
2014
|
| | | $ | 546,246 | | | | | | — | | | | | $ | 837,784 | | | | | $ | 1,141,664 | | | | | $ | 719,941 | | | | | | — | | | | | $ | 22,238 | | | | | $ | 3,267,873 | | |
NEO
|
| |
2015 MIP
|
| |
2013−2015 LTIP
|
| ||||||
Robert J. Hugin
|
| | | $ | 2,255,594 | | | | | $ | 5,114,509 | | |
Peter Kellogg
|
| | | $ | 581,893 | | | | | $ | 801,364 | | |
Mark J. Alles
|
| | | $ | 794,907 | | | | | $ | 2,647,308 | | |
Thomas O. Daniel, M.D.
|
| | | $ | 509,156 | | | | | $ | 2,565,860 | | |
Jacqualyn A. Fouse, Ph.D.
|
| | | $ | 685,836 | | | | | $ | 2,993,487 | | |
Scott A. Smith
|
| | | $ | 487,867 | | | | | $ | 372,566 | | |
Name
|
| |
Year
|
| |
Value of
Employer Contributions to the Nonqualified Plan* |
| |
Value of
Matching Contributions To the 401(k) Plan in Shares of Common Stock** |
| |
Professional
Tax and Financial Counseling |
| |
Excess
Liability Insurance Premiums |
| |
Contributions
to Health Savings Account |
| |
Other***
|
| |
Total
|
| |||||||||||||||||||||
Robert J. Hugin
|
| |
2015
|
| | | $ | 222,500 | | | | | $ | 16,186 | | | | | | — | | | | | $ | 2,455 | | | | | $ | 2,210 | | | | | | — | | | | | $ | 243,351 | | |
|
2014
|
| | | $ | 207,000 | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | $ | 2,178 | | | | | | — | | | | | $ | 231,416 | | | ||
|
2013
|
| | | $ | 189,375 | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | $ | 1,650 | | | | | | — | | | | | $ | 212,854 | | | ||
Peter Kellogg
|
| |
2015
|
| | | | — | | | | | $ | 16,186 | | | | | $ | 5,479 | | | | | $ | 2,455 | | | | | | — | | | | | | — | | | | | $ | 24,120 | | |
|
2014
|
| | | | — | | | | | $ | 7,019 | | | | | $ | 2,079 | | | | | | — | | | | | | — | | | | | | — | | | | | $ | 9,098 | | | ||
Mark J. Alles
|
| |
2015
|
| | | | — | | | | | $ | 16,186 | | | | | | — | | | | | $ | 923 | | | | | | — | | | | | | — | | | | | $ | 17,109 | | |
|
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 1,364 | | | | | | — | | | | | | — | | | | | $ | 21,272 | | | ||
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 914 | | | | | | — | | | | | | — | | | | | $ | 20,511 | | | ||
Thomas O. Daniel, M.D.
|
| |
2015
|
| | | | — | | | | | $ | 16,186 | | | | | | — | | | | | $ | 1,399 | | | | | | — | | | | | $ | 156,956 | | | | | $ | 174,541 | | |
|
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 518 | | | | | | — | | | | | $ | 127,938 | | | | | $ | 148,364 | | | ||
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | | — | | | | | $ | 78,605 | | | | | $ | 100,434 | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| |
2015
|
| | | | — | | | | | $ | 16,186 | | | | | | — | | | | | $ | 2,455 | | | | | | — | | | | | | — | | | | | $ | 18,641 | | |
|
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | | — | | | | | | — | | | | | $ | 22,238 | | | ||
|
2013
|
| | | | — | | | | | $ | 19,597 | | | | | | — | | | | | $ | 2,232 | | | | | | — | | | | | | — | | | | | $ | 21,829 | | | ||
Scott A. Smith
|
| |
2015
|
| | | | — | | | | | $ | 16,186 | | | | | | — | | | | | $ | 2,455 | | | | | | — | | | | | | — | | | | | $ | 18,641 | | |
|
2014
|
| | | | — | | | | | $ | 19,908 | | | | | | — | | | | | $ | 2,330 | | | | | | — | | | | | | — | | | | | $ | 22,238 | | |
Name
|
| |
Grant
Date |
| |
Comm
Action(1) |
| |
Estimated Potential/Future
Payouts Under Non-Equity Incentive Plan Awards(2) |
| |
Estimated Potential/Future
Payouts Under Equity Incentive Plan Awards (#)(3) |
| |
Stock
Awards Number of Shares of Stock or Units(4) |
| |
Awards
Number of Securities Underlying Options (#)(4) |
| |
Exercise
or Base Price of Stock And Options ($/Sh)(5) |
| |
Grant
Date Fair Value of PSUs Stock and Options(6) |
| ||||||||||||||||||||||||||||||||||||||||||||||||
|
Threshold
|
| |
Target
|
| |
Maximum
|
| |
Threshold
|
| |
Target
|
| |
Maximum
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(a)
|
| |
(b)
|
| | | | | | | |
(c)
|
| |
(d)
|
| |
(e)
|
| |
(f)
|
| |
(g)
|
| |
(h)
|
| |
(i)
|
| |
(j)
|
| |
(k)
|
| |
(l)
|
| |||||||||||||||||||||||||||||||||
Robert J. Hugin
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 79,500 | | | | | $ | 118.57 | | | | | $ | 3,314,498 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 2,250,000 | | | | | $ | 4,500,000 | | | | | | 14,700 | | | | | | 29,400 | | | | | | 58,800 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 3,639,867 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40,700 | | | | | $ | 109.90 | | | | | $ | 1,402,107 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 16,300 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 1,791,370 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40,700 | | | | | $ | 132.56 | | | | | $ | 1,633,291 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40,700 | | | | | $ | 114.08 | | | | | $ | 1,594,992 | | | ||
Peter N. Kellogg
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 118.57 | | | | | $ | 424,214 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 576,800 | | | | | $ | 1,153,600 | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 758,213 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 109.90 | | | | | $ | 297,130 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,500 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 384,650 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 132.56 | | | | | $ | 346,121 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 114.08 | | | | | $ | 338,005 | | | ||
| | | 12/16/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,036 | | | | | | — | | | | | $ | 115.72 | | | | | $ | 929,926 | | | ||
Mark J. Alles
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 118.57 | | | | | $ | 424,214 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 787,950 | | | | | $ | 1,575,900 | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 758,213 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 109.90 | | | | | $ | 297,130 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,500 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 384,650 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 132.56 | | | | | $ | 346,121 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 114.08 | | | | | $ | 338,005 | | | ||
| | | 12/16/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,929 | | | | | | — | | | | | $ | 115.72 | | | | | $ | 1,033,264 | | | ||
Thomas O. Daniel, M.D.
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 118.57 | | | | | $ | 424,214 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 504,700 | | | | | $ | 1,009,400 | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 758,213 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 109.90 | | | | | $ | 297,130 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,500 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 384,650 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 132.56 | | | | | $ | 346,121 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 114.08 | | | | | $ | 338,005 | | | ||
| | | 12/16/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,143 | | | | | | — | | | | | $ | 115.72 | | | | | $ | 826,588 | | | ||
Jacqualyn A. Fouse, Ph.D.
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,175 | | | | | $ | 118.57 | | | | | $ | 424,214 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 679,840 | | | | | $ | 1,359,680 | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 758,213 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 109.90 | | | | | $ | 297,130 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,500 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 384,650 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 132.56 | | | | | $ | 346,121 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 114.08 | | | | | $ | 338,005 | | | ||
| | | 12/16/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,482 | | | | | | — | | | | | $ | 115.72 | | | | | $ | 981,538 | | | ||
Scott A. Smith
|
| | | | 2/2/2015 | | | | | | 2/11/2014 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,000 | | | | | $ | 118.57 | | | | | $ | 208,459 | | |
| | | 2/17/2015 | | | | | | 2/17/2015(3)(2) | | | | | $ | — | | | | | $ | 487,500 | | | | | $ | 975,000 | | | | | | 3,100 | | | | | | 6,200 | | | | | | 12,400 | | | | | | | | | | | | — | | | | | | — | | | | | $ | 758,213 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 109.90 | | | | | $ | 297,130 | | | ||
| | | 5/4/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,500 | | | | | | — | | | | | $ | 109.90 | | | | | $ | 384,650 | | | ||
| | | 7/27/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 132.56 | | | | | $ | 346,121 | | | ||
| | | 11/9/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,625 | | | | | $ | 114.08 | | | | | $ | 338,005 | | | ||
| | | 12/16/2015 | | | | | | 2/17/2015 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,036 | | | | | | — | | | | | $ | 115.72 | | | | | $ | 929,926 | | |